Skip to content

Psychedelic Medicine

ISSN 2831-4425, 2831-4433

113 papers in the library · 717 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy

Psychedelic Medicine January 12, 2026 Kelsey T. Laird, Prabha Siddarth, Ashley Ramos et al.

Objective: Emerging evidence suggests that mystical experiences mediate the therapeutic effects of psychedelic-assisted therapy. The current study examines associations between mystical experiences and components of “set” (positive mindset, participant intentions, and spirituality) and “setting” (perceived positivity of the dosing environment) in the context of psilocybin-assisted therapy for...

A Practical Approach and Framework to Quality Management for Psychedelic Drug Development

Psychedelic Medicine January 7, 2026 Dawn Lundin

Sponsor companies and physician investigators engaged in clinical research, including those involved in psychedelic drug development, are to design quality into the clinical studies upfront as outlined in International Council for Harmonization (ICH) E8 R1, General Considerations for Clinical Studies, and ICH E6 R3, Guideline for Good Clinical Practice. Identification of what is critical to...

Effects of 5-HT 2A Receptor Activation on Oxycodone Demand after Short and Long Access Self-Administration in Male and Female Rats

Psychedelic Medicine January 7, 2026 Carter J. Richardson, Alice J. McQueney, Thomas Stevens et al.

Introduction: Oxycodone is a necessary analgesic medication but carries abuse potential. There is an urgent need to develop therapeutics to reduce abuse potential. Psychedelic compounds may be a viable option, but the behavioral and pharmacological mechanism of action is undefined. Methods: Male and female Sprague–Dawley rats were implanted with indwelling jugular catheters and allowed to...

Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019

Psychedelic Medicine December 30, 2025 Brian S. Barnett, Akhil Anand, Tatiana Falcone et al.

Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the United States using nationally representative data and to compare correlates of LSD use between lesbian, gay, and bisexual individuals (LGB) and heterosexual individuals. Method: Using National Survey on Drug Use and Health data on adults from 2015 to...

DOI: 10.1177/28314425251410086 (opens in new tab) Lysergic acid diethylamide Sexual minority Sexual orientation Heterosexuality +9

A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Psychedelic Medicine December 26, 2025 Rhianna Rich, Kelsey T. Laird, Prabha Siddarth et al.

Background: Psychedelic-assisted psychotherapy has shown promising results for treating alcohol use disorder (AUD) and other mental health conditions. Although the precise mechanisms of psychedelic therapies remain unclear, many studies report increased feelings of connectedness following psychedelic experiences. Specifically, both nature relatedness (one’s subjective sense of being connected...

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

Psychedelic Medicine December 23, 2025 Anthony L. Back, Bonnie A. Mcgregor, Lindsay Billingsley et al. 1 citation

Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an food and drug administration...

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research

Psychedelic Medicine December 19, 2025 Amanda Husein, Madalynn Traylor, M. Frances Vest et al.

Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing psychiatrists in Louisiana. Louisiana...

Exploring Access to Psychedelics Among Canadian Veterans: Pathways, Barriers, and Perceptions

Psychedelic Medicine December 17, 2025 Luis E. Contreras, Grace M Elliott, Francesco Kment et al.

Introduction:Psychedelic-assisted therapies have recently gained attention as potential novel treatments for various mental health conditions. In Canada, there has been particular interest from the veteran communities regarding the potential therapeutic impact of psychedelics. However, legal access remains limited in Canada, leading some veterans to explore alternative pathways. Here, we aimed...

DOI: 10.1177/28314425251387678 (opens in new tab) Stigma botany Perception Mental health care Confidentiality +5

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats

Psychedelic Medicine December 16, 2025 Sophie Woodruff, Meghan Hibicke, Charles D. Nichols

Introduction:Psilocybin, a classical psychedelic, has shown to produce persistent antidepressant effects, including in patients with treatment-resistant depression. In clinical practice, it is common to coprescribe benzodiazepines (BZDs) alongside antidepressants. However, our preliminary study indicated that preadministration of lorazepam diminished the antidepressant-like efficacy and...

DOI: 10.1177/28314425251393186 (opens in new tab) Psilocybin Lorazepam Pharmacology Prefrontal cortex +6

Ceremonial Psychedelic Experiences and Changes in Mental Health Outcomes in Those with Adverse Childhood Experiences

Psychedelic Medicine December 15, 2025 M. Mehmood, Rebecka Bremler, M. Spriggs et al.

Background:Adverse childhood experiences (ACEs) are known to contribute to mental health issues and interfere with response to mental health interventions. Psychedelics have been found to improve mental health outcomes; however, the exploration of the effects of psychedelics on mental health in those with higher ACEs remains limited. The present study aimed to examine mental health outcomes and...

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions: The Great Promise of Psychedelics: Evolving Human Consciousness

Psychedelic Medicine December 1, 2025 Tara Brach

By exploring the spiritual effects of psilocybin on clergy from a range of world religions, this study widens our view to consider the full evolutionary potential of the current psychedelic revolution. Throughout human history

Griffiths et al.'s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective.

Psychedelic Medicine December 1, 2025 Joseph Lorenz, Scott Hawkins, Bryan Mccarthy

Griffiths et al.'s recent "Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions" is an important study in the literature on psychedelic medicine and religious experience. In this commentary on the study, we argue: (1) The study design's implicit presupposition of perennialism in its conception of mysticism burdens it with...

“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy

Psychedelic Medicine October 8, 2025 Elise C. Tarbi, Skye A. Miner, Kabir Nigam et al. 1 citation

Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and...

DOI: 10.1177/28314425251370303 (opens in new tab) Psilocybin Existentialism Cancer Perspective graphical +6

Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review

Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.

Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...

Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis.

Psychedelic Medicine August 1, 2025 Kush V. Bhatt, Jason Compton, Em Ellerman et al. 1 citation

Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression. We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments....

Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.

Psychedelic Medicine June 1, 2025 Haley Maria Dourron, Melissa Bradley, Otto Simonsson et al. 7 citations

Prior research examining the associations between psychedelic use and general psychotic symptoms has yielded mixed findings. However, no studies have investigated the relationships between psychedelic use and specific psychotic symptoms, and whether these relationships might differ among those with liability to psychosis, namely those with a history of psychotic or bipolar disorders. Using...

DOI: 10.1089/psymed.2024.0036 (opens in new tab) Full text (opens in new tab) Bipolar disorder Psychedelics Risks Psychotic disorders +4

Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis.

Psychedelic Medicine June 1, 2025 Rahul Katkar, Ashley M Perez, Murat Altinay et al. 4 citations

Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications. In this retrospective observational study, posts and comments on the "r/LSD" subreddit reporting gender-themed LSD experiences...

DOI: 10.1089/psymed.2024.0025 (opens in new tab) Full text (opens in new tab) LSD Gender dysphoria Gender identity Online forum +1

Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.

Psychedelic Medicine June 1, 2025 Sara Shoar, Alissa Bazinet, Chaitra Jairaj 2 citations

In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the...

DOI: 10.1089/psymed.2024.0033 (opens in new tab) Full text (opens in new tab) Postpartum depression Pregnancy Reproductive health Women’s health +2

Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans.

Psychedelic Medicine June 1, 2025 Sierra Carter, Grace Packard, Jessica L Maples-Keller

Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests that psychedelic-assisted therapy (PAT) is an effective treatment for post-traumatic stress disorder and depression. It is important to understand perceptions of PAT among populations with unmet mental health needs. We conducted four focus groups to...

DOI: 10.1089/psymed.2024.0015 (opens in new tab) Full text (opens in new tab) Diversity Psychedelics for therapy Urban black americans Trust +5

Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.

Psychedelic Medicine June 1, 2025 Olivia M Dhaliwal, Lukas Bobak, Brian S. Barnett

With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedioxymethamphetamine in the treatment of posttraumatic stress disorder, the likelihood of psychedelic medication becoming approved for clinical use in the United States is high. Psychedelic-assisted therapy (PAT) may have a high demand in rural America,...

DOI: 10.1089/psymed.2024.0018 (opens in new tab) Full text (opens in new tab) Rural psychiatry Rural health disparities Rural medicine access Psychedelic-assisted therapy pat +4

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

Psychedelic Medicine May 16, 2025 Roland R. Griffiths, William A. Richards, Robert L. Jesse et al. 14 citations

Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy....

Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review

Psychedelic Medicine April 28, 2025 Shakila Meshkat, Howell Fang, Rachel Sousa-Ho et al.

Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress

Psychedelic Medicine April 22, 2025 Sean M. Viña 6 citations

Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions:...

Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers

Psychedelic Medicine April 21, 2025 Luke Flynn, Mary Rondeau, Martin Krsak et al. 1 citation

Introduction: Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder. Ketamine-assisted psychotherapy (KAP) is part of an emerging model of psychedelic medicine that employs psychoactive agents to support the psychotherapeutic...

A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

Psychedelic Medicine April 14, 2025 Caroline Hayes

As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean...